Biopharmaceutical company developing small molecule therapies for rare muscle disorders.
Edgewise Therapeutics, Inc., headquartered in Boulder, Colorado, is a pioneering biopharmaceutical company dedicated to advancing small molecule therapies for musculoskeletal diseases. Since its inception in 2017, the company has focused on developing innovative treatments that target the underlying causes of genetic muscle disorders.
At the forefront of Edgewise Therapeutics' portfolio is EDG-5506, its lead product candidate. EDG-5506 is an orally administered small molecule specifically designed to address dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. The compound has successfully completed a Phase 1 clinical trial, demonstrating promising potential in addressing these debilitating conditions.
Edgewise Therapeutics distinguishes itself through a pipeline of precision medicine product candidates. These therapies are strategically developed to target key muscle proteins and modulators, aiming to provide effective treatments for genetically defined muscle disorders. By leveraging cutting-edge research and development, the company aims to bring transformative therapies to patients in need.
Driven by a commitment to innovation and patient-centric care, Edgewise Therapeutics collaborates with leading researchers and healthcare professionals. With a robust scientific approach and strategic focus on musculoskeletal diseases, the company continues to advance its mission of improving outcomes and quality of life for individuals affected by genetic muscle disorders worldwide.